Immunogenicity and Safety of a Full-Dose Regimen of Cell Culture-Derived Quadrivalent Inactivated Influenza Vaccine in Children Aged 6–35 Months: Results from a Multinational Phase 3 Randomised Controlled Trial
NBP607-QIV administered at a 0.5 mL dose demonstrated acceptable immunogenicity and a safety profile comparable to that of a licensed trivalent influenza vaccine in children aged 6-35 months, supporting its use in this paediatric population.
Authors
- Yoonyeong Lee (ORCID: https://orcid.org/0000-0002-1587-4961)
- Hwang Min Kim
- Su Eun Park
- Yun Kyung Kim (ORCID: https://orcid.org/0000-0003-4396-8671)
- Hye‐Kyung Cho (ORCID: https://orcid.org/0000-0003-0990-1350)
- Dae Sun Jo (ORCID: https://orcid.org/0000-0002-3141-9539)
- Ho Keun Park
- Yae‐Jean Kim (ORCID: https://orcid.org/0000-0002-8367-3424)
- Yoonsun Yoon (ORCID: https://orcid.org/0000-0003-0187-3922)
- Nam Hee Kim (ORCID: https://orcid.org/0000-0002-1793-1392)
- Ki Hwan Kim (ORCID: https://orcid.org/0000-0001-6145-3909)
- Seon Hee Shin
- Eun Young Cho
- Jina Lee
Institutions
- Gachon University (KR)
- Yonsei University (KR)
- University of Ulsan (KR)
- The Catholic University of Korea Incheon St. Mary's Hospital (KR)
- Inje University Ilsan Paik Hospital (KR)
- Chungnam National University Hospital (KR)
- Pusan National University Yangsan Hospital (KR)
- Hallym University Dongtan Sacred Heart Hospital (KR)
- Korea University (JP)
- Pusan National University (KR)
- Korea Research Institute of Bioscience and Biotechnology (KR)
- Jeonbuk National University (KR)
- Sungkyunkwan University (KR)
- Catholic University of Korea (KR)
Publication Details
- Journal
- Vaccines
- Published
- 2026-04-13
- DOI
- https://doi.org/10.3390/vaccines14040341
- Primary Topic
- Influenza Virus Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00